Takeda Pharmaceutical (NYSE:TAK) Updates Fiscal 2022 Earnings Guidance

Takeda Pharmaceutical (NYSE:TAKGet a rating) released an update to its fiscal 2022 earnings guidance Thursday morning. The company provided earnings per share (EPS) guidance of $3.80 to $3.80 for the period. The company released revenue forecasts of $28.46 billion to $28.46 billion.

Performance of Takeda Pharmaceutical Stocks

NYSE:TAK traded down $0.06 in midday trading on Thursday, hitting $13.07. The stock recorded trading volume of 72,108 shares, compared to an average trading volume of 4,045,435 shares. The stock has a market capitalization of $40.53 billion, a price/earnings ratio of 24.32, a P/E/G ratio of 0.58 and a beta of 0.68. The company has a 50-day simple moving average of $13.19 and a 200-day simple moving average of $13.85. Takeda Pharmaceutical has a 52-week low of $12.28 and a 52-week high of $15.36. The company has a current ratio of 1.15, a quick ratio of 0.75 and a debt ratio of 0.62.

Takeda Pharmaceutical (NYSE:TAKGet a rating) last released its quarterly results on Thursday, October 27. The company reported EPS of $0.52 for the quarter. The company posted revenue of $7.26 billion for the quarter. Takeda Pharmaceutical had a net margin of 5.60% and a return on equity of 12.76%. On average, research analysts expect Takeda Pharmaceutical to post earnings per share of 2.1 for the current fiscal year.

Analyst upgrades and downgrades

A number of research analysts have recently commented on the stock. Cowen upgraded Takeda Pharmaceutical shares from a market performance rating to an outperformance rating in a Tuesday, July 19 research report. Cowen upgraded Takeda Pharmaceutical shares from a market performance rating to an outperformance rating and raised its price target for the company from $21.00 to $24.00 in a Tuesday 19 research report. July. Finally, Jefferies Financial Group downgraded shares of Takeda Pharmaceutical from a buy rating to a hold rating in a Friday, July 29 research report.

Takeda Pharmaceutical Institutional Trading

A number of institutional investors and hedge funds have recently changed their TAK holdings. Raymond James & Associates increased its stake in Takeda Pharmaceutical shares by 28.2% in the first quarter. Raymond James & Associates now owns 132,226 shares of the company worth $1,893,000 after purchasing an additional 29,087 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Takeda Pharmaceutical by 26.1% in the first quarter. Bank of New York Mellon Corp now owns 63,801 shares of the company valued at $914,000 after purchasing an additional 13,205 shares during the period. American Century Companies Inc. increased its stake in Takeda Pharmaceutical by 14.5% in the 1st quarter. American Century Companies Inc. now owns 70,780 shares of the company valued at $1,014,000 after purchasing an additional 8,941 shares during the period. HighTower Advisors LLC increased its stake in Takeda Pharmaceutical by 7.5% in Q1. HighTower Advisors LLC now owns 28,326 shares of the company valued at $404,000 after purchasing an additional 1,983 shares during the period. Finally, Bank of Montreal Can increased its stake in Takeda Pharmaceutical by 29.6% in the 1st quarter. Bank of Montreal Can now owns 54,780 shares of the company valued at $791,000 after purchasing an additional 12,497 shares during the period. 1.96% of the shares are currently held by institutional investors and hedge funds.

About Takeda Pharmaceutical

(Get a rating)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing and licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, the rest of Asia and internationally. It offers pharmaceutical products in the fields of gastroenterology, rare diseases, plasma-derived therapies, oncology and neurosciences.

Featured Articles

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Takeda Pharmaceutical, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five actions that top analysts are quietly whispering to their clients to buy now before the market spreads…and Takeda Pharmaceutical was not on the list.

Although Takeda Pharmaceutical currently has a “moderate buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here